|
시장보고서
상품코드
2050499
로사르탄 칼륨 정제 시장 : 용량별, 적응증별, 연령층별, 유형별, 제형별, 포장 형태별, 유통 채널별, 최종사용자별, 지역별Losartan Potassium Tablets Market, By Strength, By Indication, By Age Group, By Type, By Formulation Type, By Packaging Type, By Distribution Channel, By End User, By Geography |
||||||
로사르탄 칼륨 정제 시장은 2026년에 28억 2,000만 달러로 추정되고 있으며, 2033년까지 44억 7,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 28억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 6.80% | 2033년 시장 규모 예측 : | 44억 7,000만 달러 |
세계의 로사르탄 칼륨 정제 시장은 전 세계에서 널리 퍼져 있는 고혈압 및 관련 심혈관계 질환에 대응하는 심혈관계 의약품 산업의 중요한 부문입니다. 안지오텐신 수용체 길항제(ARB)인 로사르탄 칼륨은 안지오텐신 II 수용체를 선택적으로 차단하여 혈관 수축과 알도스테론 분비를 억제하는 작용을 합니다. 그 결과, 혈압이 낮아지고 심혈관계 결과가 개선됩니다.
이 치료제는 ACE 억제제 대비 우수한 부작용 프로파일, 특히 마른기침을 유발하지 않아 고혈압 치료제에 대한 내약성이 낮은 환자들에게 선호되는 치료제로 각광을 받고 있습니다. 시장에는 다양한 용량의 제품과 제형이 있으며, 지역마다 다른 다양한 환자층에 대응하기 위해 다양한 용량의 제품과 제형이 있습니다. 전 세계 심혈관 질환 부담 증가, 고령화, 고혈압 관리에 대한 인식이 높아짐에 따라 로사르탄 칼륨 정제에 대한 수요는 지속적으로 크게 증가하고 있습니다. 시장 역학은 특허 만료로 인한 제네릭 의약품과의 경쟁, 새로운 제형에 대한 규제 당국의 승인, 신흥 국가의 의료 인프라 구축, 주요 순환기 학회의 치료 지침 개정 등의 요인에 영향을 받고 있으며, 이 시장은 광범위한 강압제 치료 분야에서 필수적인 요소로 자리매김하고 있습니다. 필수적인 요소로 자리매김하고 있습니다.
시장 역학
세계의 로사르탄 칼륨 정제 시장은 탄탄한 성장 궤도를 지원하는 몇 가지 강력한 촉진요인에 의해 주도되고 있습니다. 세계보건기구(WHO)의 추산에 따르면 전 세계에서 11억 3천만 명 이상이 앓고 있는 고혈압의 유병률 증가와 심혈관 위험 관리 및 조기 개입 전략에 대한 인식이 높아진 것이 주요 요인으로 작용하고 있습니다. 세계 인구의 고령화는 시장 확대에 크게 기여하고 있습니다. 고혈압 발병률은 나이가 들면서 크게 증가하는 반면, 좌식 생활습관, 고나트륨 섭취, 스트레스 관련 요인 등 생활습관의 변화로 인해 항고혈압 치료가 필요한 환자층이 더욱 확대되고 있기 때문입니다. 또한 ARB(안지오텐신 수용체 길항제)가 ACE 억제제 대비 우수한 내약성, 특히 혈관성 부종과 지속적인 마른기침이 없다는 점은 의사의 선택과 환자의 복약 순응도를 높여 시장 수요를 유지하고 있습니다.
그러나 시장에는 눈에 띄는 제약도 존재합니다. 브랜드 제제의 특허만료에 따른 제네릭 의약품과의 치열한 경쟁으로 인해 제조사들은 가격 하락과 이익률 압박을 받고 있습니다. 또한 의약품 승인 및 제조 컴플라이언스에 대한 엄격한 규제 요건은 막대한 운영 비용과 개발 기간의 연장을 초래하고 있습니다. 또한 칼슘길항제, 베타 차단제, 새로운 병용요법 등 대체 강압제 계열의 등장으로 시장 점유율 확대에 대한 경쟁적 압력이 발생하고 있습니다. 그럼에도 불구하고 아시아태평양, 라틴아메리카, 아프리카 등 신흥 시장에서는 의료 인프라 확충, 의료비 증가, 의약품에 대한 접근성 확대에 따라 큰 성장 기회가 창출되고 있습니다. 로살탄과 보완적인 강압제를 결합한 혁신적인 병용요법의 개발은 수익성 높은 성장의 길을 보여주고 있으며, 디지털 헬스 통합과 맞춤형 의료 접근법은 환자 모니터링 강화와 치료 최적화를 위한 잠재력을 가지고 있습니다. 이를 통해 경쟁의 어려움에도 불구하고 시장은 장기적으로 지속가능한 확장을 위한 토대를 마련하고 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 세계의 로사르탄 칼륨 정제 시장의 주요 기업 개요을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계의 로사르탄 칼륨 정제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 로사르탄 칼륨 정제 시장을 분석하는 데 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 로사르탄 칼륨 정제 시장 : 강도별, 2021-2033년
제5장 세계의 로사르탄 칼륨 정제 시장 : 적응증별, 2021-2033년
제6장 세계의 로사르탄 칼륨 정제 시장 : 연령층별, 2021-2033년
제7장 세계의 로사르탄 칼륨 정제 시장 : 유형별, 2021-2033년
제8장 세계의 로사르탄 칼륨 정제 시장 : 제제 유형별, 2021-2033년
제9장 세계의 로사르탄 칼륨 정제 시장 : 포장 유형별, 2021-2033년
제10장 세계의 로사르탄 칼륨 정제 시장 : 유통 채널별, 2021-2033년
제11장 세계의 로사르탄 칼륨 정제 시장 : 최종사용자별, 2021-2033년
제12장 세계의 로사르탄 칼륨 정제 시장 : 지역별, 2021-2033년
제13장 경쟁 구도
제14장 애널리스트의 제안
제15장 참고 문헌 및 조사 방법
KSA 26.06.10Losartan Potassium Tablets Market is estimated to be valued at USD 2.82 Bn in 2026 and is expected to reach USD 4.47 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.82 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.80% | 2033 Value Projection: | USD 4.47 Bn |
The global losartan potassium tablets market represents a crucial segment within the cardiovascular pharmaceutical industry, addressing the widespread prevalence of hypertension and related cardiovascular disorders worldwide. Losartan potassium, an Angiotensin Receptor Blocker (ARB), functions by selectively blocking angiotensin II receptors, thereby preventing vasoconstriction and aldosterone secretion, which ultimately leads to reduced blood pressure and improved cardiovascular outcomes.
This therapeutic class has gained significant traction due to its favorable side effect profile compared to ACE inhibitors, particularly the absence of dry cough, making it a preferred choice for patients with hypertension intolerance issues. The market encompasses various dosage strengths and formulations, catering to diverse patient populations across different geographical regions. With the increasing global burden of cardiovascular diseases, aging demographics, and rising awareness about hypertension management, the demand for Losartan Potassium Tablets continues to expand substantially. The market dynamics are influenced by factors including patent expirations leading to generic competition, regulatory approvals for new formulations, healthcare infrastructure development in emerging economies, and evolving treatment guidelines from major cardiology associations, positioning this market as a vital component of the broader antihypertensive therapeutics landscape.
Market Dynamics
The global losartan potassium tablets market is propelled by several compelling drivers that underscore its robust growth trajectory, with the primary catalyst being the escalating prevalence of hypertension globally, affecting over 1.13 billion people worldwide according to WHO estimates, coupled with increasing awareness about cardiovascular risk management and early intervention strategies. The aging global population demographic significantly contributes to market expansion, as hypertension incidence rises substantially with age, while lifestyle changes including sedentary behavior, high sodium intake, and stress-related factors further amplify the patient pool requiring antihypertensive therapy. Additionally, the superior tolerability profile of ARBs compared to ACE inhibitors, particularly the absence of angioedema and persistent dry cough, drives physician preference and patient compliance, thereby sustaining market demand.
However, the market faces notable restraints including intense generic competition following patent expirations of branded formulations, leading to significant price erosion and margin compression for manufacturers, while stringent regulatory requirements for drug approval and manufacturing compliance impose substantial operational costs and timeline extensions. Furthermore, the availability of alternative antihypertensive classes such as calcium channel blockers, beta-blockers, and newer combination therapies creates competitive pressure on market share growth. Nevertheless, substantial opportunities emerge from expanding healthcare infrastructure in developing economies, increasing healthcare expenditure, and growing pharmaceutical access in emerging markets including Asia-Pacific, Latin America, and Africa. The development of innovative combination therapies incorporating losartan with complementary antihypertensive agents presents lucrative growth avenues, while digital health integration and personalized medicine approaches offer potential for enhanced patient monitoring and treatment optimization, positioning the market for sustained long-term expansion despite competitive challenges.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global losartan potassium tablets market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Merck and Co. (MSD), Teva Pharmaceutical Industries, Torrent Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Aurobindo Pharma, Lupin Limited, Zydus Lifesciences, Alembic Pharmaceuticals, Viatris (Mylan), Apotex Inc., Hikma Pharmaceuticals, Cipla Limited, Sandoz (Novartis Division), and Intas Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global losartan potassium tablets market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global losartan potassium tablets market
Market Segmentation
- Strength Insights (Revenue, USD Bn, 2021 - 2033)
- 25 mg
- 50 mg
- 100 mg
- Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Hypertension
- Hypertensive Patients with Left Ventricular Hypertrophy (LVH)
- Type 2 Diabetes with Nephropathy
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adult
- Pediatric
- Geriatric
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Branded
- Generic
- Formulation Type Insights (Revenue, USD Bn, 2021 - 2033)
- Immediate-Release Tablets
- Extended-Release Tablets
- Packaging Type Insights (Revenue, USD Bn, 2021 - 2033)
- Blister Packs
- Bottles
- Strip Packs
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Merck (MSD)
- Teva Pharmaceutical Industries
- Torrent Pharmaceuticals
- Sun Pharmaceutical Industries
- Reddy's Laboratories
- Aurobindo Pharma
- Lupin Limited
- Zydus Lifesciences
- Alembic Pharmaceuticals
- Viatris (Mylan)
- Apotex Inc.
- Hikma Pharmaceuticals
- Cipla Limited
- Sandoz (Novartis Division)
- Intas Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Losartan Potassium Tablets Market, By Strength
- Global Losartan Potassium Tablets Market, By Indication
- Global Losartan Potassium Tablets Market, By Age Group
- Global Losartan Potassium Tablets Market, By Type
- Global Losartan Potassium Tablets Market, By Formulation Type
- Global Losartan Potassium Tablets Market, By Packaging Type
- Global Losartan Potassium Tablets Market, By Distribution Channel
- Global Losartan Potassium Tablets Market, By End User
- Global Losartan Potassium Tablets Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Losartan Potassium Tablets Market, By Strength, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- 25 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 50 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 100 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Losartan Potassium Tablets Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hypertensive Patients with Left Ventricular Hypertrophy (LVH)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Type 2 Diabetes with Nephropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Losartan Potassium Tablets Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Losartan Potassium Tablets Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Losartan Potassium Tablets Market, By Formulation Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Immediate-Release Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Extended-Release Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Losartan Potassium Tablets Market, By Packaging Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Blister Packs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bottles
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Strip Packs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Losartan Potassium Tablets Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Losartan Potassium Tablets Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Losartan Potassium Tablets Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Packaging Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Packaging Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Packaging Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Packaging Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Packaging Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Packaging Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Merck (MSD)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Torrent Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Lifesciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alembic Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris (Mylan)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz (Novartis Division)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intas Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
